Explore
Validate
LearnHPA008356
antibody from Atlas Antibodies
Targeting: RET
CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA008356 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA008356, RRID:AB_1847232
- Product name
- Anti-RET
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human RET, Gene description: ret proto-oncogene, Alternative Gene Names: CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51, Validated applications: ICC, IHC, Uniprot ID: P07949, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references RET overexpression leads to increased brain metastatic competency in luminal breast cancer
RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas
Expression of the Body-Weight Signaling Players: GDF15, GFRAL and RET and their clinical relevance in Gastric Cancer
Profiling post-centrifugation delay of serum and plasma with antibody bead arrays
RET is a potential tumor suppressor gene in colorectal cancer
Jagust P, Powell A, Ola M, Watson L, de Pablos-Aragoneses A, García- Gómez P, Fallon R, Bane F, Heiland M, Morris G, Cavanagh B, McGrath J, Ottaviani D, Hegarty A, Cocchiglia S, Sweeney K, MacNally S, Brett F, Cryan J, Beausang A, Morris P, Valiente M, Hill A, Varešlija D, Young L
JNCI: Journal of the National Cancer Institute 2024;116(10):1632-1644
JNCI: Journal of the National Cancer Institute 2024;116(10):1632-1644
RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas
Garcia-Rendueles A, Chenlo M, Oroz-Gonjar F, Solomou A, Mistry A, Barry S, Gaston-Massuet C, Garcia-Lavandeira M, Perez-Romero S, Suarez-Fariña M, Pradilla-Dieste A, Dieguez C, Mehlen P, Korbonits M, Alvarez C
Oncogene 2021;40(45):6354-6368
Oncogene 2021;40(45):6354-6368
Expression of the Body-Weight Signaling Players: GDF15, GFRAL and RET and their clinical relevance in Gastric Cancer
Buchholz K, Antosik P, Grzanka D, Gagat M, Smolińska M, Grzanka A, Gzil A, Kasperska A, Klimaszewska-Wiśniewska A
Journal of Cancer 2021;12(15):4698-4709
Journal of Cancer 2021;12(15):4698-4709
Profiling post-centrifugation delay of serum and plasma with antibody bead arrays
Qundos U, Hong M, Tybring G, Divers M, Odeberg J, Uhlen M, Nilsson P, Schwenk J
Journal of Proteomics 2013;95
Journal of Proteomics 2013;95
RET is a potential tumor suppressor gene in colorectal cancer
Luo Y, Tsuchiya K, Il Park D, Fausel R, Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J, Grady W
Oncogene 2012;32(16):2037-2047
Oncogene 2012;32(16):2037-2047
No comments: Submit comment
No validations: Submit validation data